Sarepta Therapeutics Cash Flow - Quarterly (NASDAQ:SRPT)

Add to My Stocks
$32.02 $1.87 (6.2%) SRPT stock closing price Feb 24, 2017 (Closing)

The Sarepta Therapeutics cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. Financials statements like the income statement and balance sheet show that the company has Sarepta Therapeutics profits and Sarepta Therapeutics debt, while the cash flow statement provides details of cash flow movments. The cash flow statement is essetial while conducting the Sarepta Therapeutics cash flow analysis and can be used to measure the operating performance of Sarepta Therapeutics compared to various industry peers like AVXS stock and HALO stock. View details of Sarepta Therapeutics cash flows for latest & last 40 quarters.

show more
Annual
Quarterly
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2016-Q3 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1
Sarepta Therapeutics Net Income Cash Flow
-178.81M-59.77M-220.03M-155.34M-103.41M-61.55M-135.78M-91.37M-62.14M-28.27M
Depreciation Depletion Amortization Cash-Flow4.42M1.63M5.89M4.68M3.18M1.59M6.12M4.34M2.61M1.04M
Net Increase (Decrease) in Assets Liabilities-13.83M-9.4M31.98M6.51M8.12M2.32M-22.13M-33.5M-25.24M-8.63M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net23.64M6.85M32.68M25.94M20.21M14.28M23.26M17.44M17.01M7.59M
Sarepta Therapeutics Net Cash from (used by) Operating Activities
-164.58M-60.68M-149.46M-118.19M-71.87M-43.34M-128.53M-103.09M-67.76M-28.26M
Increase (Decrease) in Prop Plant And Equipment-2.42M-1.16M-3.4M-2.31M-1.16M-0.53M-25.44M-22.3M-9.84M-5.32M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments112.1M21M13.24M81.52M49.01M44.75M-132.2M-182.34M-174.69M-176.66M
Other Cash Inflow (Outflow) from Investment Activities-1.09M-0.41M-1.43M-0.98M-0.64M-0.39M-1.38M-1.06M-0.62M-0.29M
Sarepta Therapeutics Net Cash from (used by) Invesment Activities
108.58M19.42M8.41M78.22M47.21M43.82M-159.03M-205.7M-185.16M-182.28M
Issuance (Purchase) of Equity Shares375.91M1.48M130.8M5.2M0.97M0.43M104.24M104.2M98.77M2.71M
Issuance (Repayment) of Debt Securities-5.07M-2.52M17M17.02M19.68M-0.02M-0.09M-0.07M-0.04M-0.02M
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Sarepta Therapeutics Net Cash from (used by) Financing Activities
370.84M-1.03M147.8M22.23M20.65M0.4M104.15M104.13M98.72M2.69M
Effect of Exchange Rate Changes on Cash----------
Sarepta Therapeutics Net Change in Cash & Cash Equivalents
314.83M-42.3M6.75M-17.73M-4.01M0.88M-183.41M-204.66M-154.21M-207.86M
Cash & Equivalents at Beginning of Year73.55M187.66M39.9M33.58M48.27M11.19M24.8M20.15M34.59M16.65M
Cash & Equivalents at Year End395.14M38M80.3M55.81M69.53M74.43M73.55M52.29M102.75M49.1M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Cash flow for another ticker

1:11
SRPT
Sarepta Therapeutics stock comparison chart provides an easy way to compare the stock price with peers along with details of Sarepta Therapeutics stock price history. Apart from the Sarepta Therapeutics stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc. , and was $-164.58M for SRPT in last quarter report.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $370.84M for Sarepta Therapeutics.
  • .